CHA Bundang Medical Center

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors	Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, liver disorder, neoplasm, stomach disorder, uterine disorder	Active, not recruiting	Phase 1 / Phase 2	2026-02-24		NCT05438420
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD	Diabetes Complications, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, diabetes mellitus, diabetic kidney disease, endocrine system disorder, kidney disorder, urinary system disorder	Recruiting	Phase 2	2025-07-18		NCT06962098

Clinical trials